Alnylam Pharmaceuticals (ALNY) net assets (shareholders' equity)
Alnylam Pharmaceuticals (ALNY) had net assets of $789.18M at the end of fiscal 2025 (December 31, 2025). That is 1076.3% higher than the $67.09M of fiscal 2024. Figures as of 19 Nov 2026, 02:23 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Net assets, fiscal 2025
- $789.18M
- Change on fiscal 2024
- +1076.3%
- Growth, 5 years
- −4.9% a year
- Growth, 10 years
- −4.6% a year
- Highest on record
- $1.77Bfiscal 2017
- Lowest on record
- -$220.64Mfiscal 2023
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Alnylam Pharmaceuticals net assets (shareholders' equity), in more detail
Over the five fiscal years to 2025 net assets shrank at a compound 4.9% a year; over ten years the rate was −4.6% a year. Across the 18 fiscal years on record (2008–2025), the highest was $1.77B in fiscal 2017 and the lowest -$220.64M in fiscal 2023.
Net assets by fiscal year
Alnylam Pharmaceuticals net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2025 | $789.18M | 1,076.3% up | |
| 2024 | $67.09M | — | |
| 2023 | -$220.64M | — | |
| 2022 | -$158.22M | 126.9% down | |
| 2021 | $588.20M | 42.1% down | |
| 2020 | $1.02B | 29.4% down | |
| 2019 | $1.44B | 10.5% up | |
| 2018 | $1.30B | 26.3% down | |
| 2017 | $1.77B | 92.0% up | |
| 2016 | $920.22M | 27.2% down | |
| 2015 | $1.26B | 35.1% up | |
| 2014 | $936.27M | 246.3% up | |
| 2013 | $270.35M | 101.7% up | |
| 2012 | $134.05M | 13.6% up | |
| 2011 | $118.00M | 25.4% down | |
| 2010 | $158.23M | 11.1% down | |
| 2009 | $177.97M | 12.0% down | |
| 2008 | $202.13M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Net assets at health care companies of similar size
| Company | Net assets | Fiscal year |
|---|---|---|
| Tenet Healthcare THC | $4.22B | 2025 |
| BioNTech BNTX | €19.22B | 2025 |
| Guardant Health GH | -$99.31M | 2025 |
| Alnylam Pharmaceuticals ALNY | $789.18M | 2025 |
| Zimmer Biomet Holdings ZBH | $12.70B | 2025 |
| Medpace Holdings MEDP | $459.07M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Alnylam Pharmaceuticals, figure by figure
- Alnylam Pharmaceuticals market cap
- Alnylam Pharmaceuticals revenue
- Alnylam Pharmaceuticals earnings
- Alnylam Pharmaceuticals earnings per share (EPS)
- Alnylam Pharmaceuticals P/E ratio
- Alnylam Pharmaceuticals P/S ratio
- Alnylam Pharmaceuticals P/B ratio
- Alnylam Pharmaceuticals free cash flow
- Alnylam Pharmaceuticals operating margin
- Alnylam Pharmaceuticals dividend
- Alnylam Pharmaceuticals shares outstanding
- Alnylam Pharmaceuticals total debt
- Alnylam Pharmaceuticals cash on hand
- Alnylam Pharmaceuticals total assets
- Alnylam Pharmaceuticals total liabilities
- Alnylam Pharmaceuticals return on equity (ROE)
- Alnylam Pharmaceuticals return on invested capital (ROIC)
Alnylam Pharmaceuticals (ALNY) overview: price, valuation and scorecardAll health care companies by market value
Alnylam Pharmaceuticals net assets (shareholders' equity): questions and answers
What are Alnylam Pharmaceuticals's net assets?
Alnylam Pharmaceuticals (ALNY) had net assets of $789.18M at the end of fiscal 2025 (December 31, 2025). That is 1076.3% higher than the $67.09M of fiscal 2024.
What is the growth rate of Alnylam Pharmaceuticals's net assets?
Over the five fiscal years to 2025 net assets shrank at a compound 4.9% a year; over ten years the rate was −4.6% a year.
What are the highest and lowest net assets figures on record for Alnylam Pharmaceuticals?
Across the 18 fiscal years on record (2008–2025), the highest was $1.77B in fiscal 2017 and the lowest -$220.64M in fiscal 2023.
How is Alnylam Pharmaceuticals's net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Alnylam Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals (ALNY) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/ALNY/net-assets
Underlying data: the company's filings with the SEC and Yahoo Finance.